Enter your email address
Submit
Write your message
Iranian Journal of Breast Diseases
Back to the articles list |
Back to browse issues page
Ethics code: Ref 1: date:2025/05/01
Zahraa AG AL Ghuraibawi1 
, Istikrar Muslem Hade1 , Ali Abd AL-Hussain Mahdi2 , Mareym Alkhaiat *3 , Zainab Ghazi Sadeq4
, Istikrar Muslem Hade1 , Ali Abd AL-Hussain Mahdi2 , Mareym Alkhaiat *3 , Zainab Ghazi Sadeq4
1- Iraqi National Cancer Research Center, University of Baghdad, Iraq
2- Middle Technical University, Baghdad, Iraq
3- Iraq Natural History Research Center and Museum, University of Baghdad, Iraq ,maryam.m@nhm.uobaghdad.edu.iq
4- Iraq Natural History Research Center and Museum, University of Baghdad, Iraq
2- Middle Technical University, Baghdad, Iraq
3- Iraq Natural History Research Center and Museum, University of Baghdad, Iraq ,
4- Iraq Natural History Research Center and Museum, University of Baghdad, Iraq
Abstract: (30 Views)
Introduction: Breast cancer is the most common malignancy among women worldwide. Interleukin-41 (IL-41) is a novel cytokine with immunomodulatory functions. This study aimed to evaluate serum IL-41 levels in breast cancer patients compared with healthy women.
Methods: A case–control study was conducted on 60 breast cancer patients (20–41 y) and 30 healthy age-matched women (20–40 y) recruited from the Teaching Oncology Hospital, Baghdad (Dec 2023–Mar 2024). Demographic data were recorded. Serum IL-41 was measured using ELISA; liver enzymes GOT and GPT were assessed by spectrophotometry. Mann–Whitney U test and Cliff’s delta were used for analysis.
Results: Median IL-41 levels were significantly higher in patients compared to controls (p<0.001, Δ=0.75; p=0.002, Δ=0.80). GPT was also elevated in patients (p=0.004, Δ=0.45; p=0.01, Δ=0.60), while GOT showed no significant difference (p>0.05).
Conclusion: IL-41 may serve as a promising biomarker for breast cancer independent of age. Elevated GPT may indicate hepatic involvement. Further studies are required to validate these findings.
Methods: A case–control study was conducted on 60 breast cancer patients (20–41 y) and 30 healthy age-matched women (20–40 y) recruited from the Teaching Oncology Hospital, Baghdad (Dec 2023–Mar 2024). Demographic data were recorded. Serum IL-41 was measured using ELISA; liver enzymes GOT and GPT were assessed by spectrophotometry. Mann–Whitney U test and Cliff’s delta were used for analysis.
Results: Median IL-41 levels were significantly higher in patients compared to controls (p<0.001, Δ=0.75; p=0.002, Δ=0.80). GPT was also elevated in patients (p=0.004, Δ=0.45; p=0.01, Δ=0.60), while GOT showed no significant difference (p>0.05).
Conclusion: IL-41 may serve as a promising biomarker for breast cancer independent of age. Elevated GPT may indicate hepatic involvement. Further studies are required to validate these findings.
Type of Study: Research |
Subject:
Diagnosis, treatment, rehabilitation
Received: 2025/03/15 | Accepted: 2025/08/26
Received: 2025/03/15 | Accepted: 2025/08/26
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
